DOC

Hereditary Angieoedema - Pipeline Review, Q4 2010

By Tammy Foster,2014-03-28 17:54
8 views 0
Hereditary Angieoedema - Pipeline Review, Q4 2010

/wEPDwUKLTUyOT

    Hereditary Angieoedema - Pipeline

    Review, Q4 2010

    联系购买电话?010-82863480 公司名称?佐思信息 公司地址?北京市海淀区

    苏州街18号院长远天地大厦A2 1008-1室?100080?

    发布日期?201011

    摘要

    "Hereditary Angieoedema - Pipeline Review, Q4 2010

    Summary

    Global Markets Direct’s, “Hereditary Angieoedema Pipeline Review 2010, Q4 2010”, provides an overview into the Hereditary Angieoedema therapeutic pipeline. This report provides information on the current developmental pipeline, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews the key players and their products under development for Hereditary Angieoedema. “Hereditary Angieoedema-Pipeline Review 2010, Q4 2010”

    is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company/University’s website, SEC filings, investor presentations and featured press releases, both from company/university sites and industry-specific third party sources, put together with in-house

    assessment, by Global Markets Direct’s team of industry experts.

    Scope

    - A snapshot of the global therapeutic scenario for Hereditary Angieoedema.

    - Review of the Hereditary Angieoedema pipeline products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Includes pipeline products based on various stages of development ranging from discovery till registration stages.

    - Includes pipeline projects on the basis of monotherapy and combined therapeutics.

    - Study of the Hereditary Angieoedema pipeline on the basis of therapeutic class, route of administration and molecule type.

    - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

    - Key discontinued pipeline projects.

    - Latest news and deals relating to the products.

    Reasons to buy

    - Identify and understand various therapeutics under development for Hereditary Angieoedema.

    - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

    - Get an insight into important and diverse types of therapeutics in pipeline for Hereditary Angieoedema and understand the trends and players likely to impact the global Hereditary Angieoedema market in future.

    - Devise corrective measures for pipeline projects by understanding Hereditary Angieoedema pipeline depth and focus and the future of Hereditary Angieoedema therapeutics.

    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. - Avoid Intellectual Property Rights related issues.

    - Do deals with an understanding of the mergers and partnerships that have shaped the sector."

目录

    "1 Table of Contents

    1.1 List of Tables

    1.2 List of Figures

    2 Introduction

    2.1 Global Markets Direct Report Coverage

    3 Introduction

    3.1 About Hereditary Angieoedema

    3.2 An Overview of Hereditary Angieoedema Therapeutics

    4 Hereditary Angieoedema Therapeutics Development

    4.1 An Overview of Pipeline Products for Hereditary Angieoedema 4.2 Hereditary Angieoedema Therapeutics under Development by

Companies

    4.3 Hereditary Angieoedema Therapeutics under Investigation by Universities/Institutes

    4.4 Late Clinical Stage Products

    4.4.1 Comparative Analysis

    4.4.2 Late Clinical Stage Products - Companies

    4.4.3 Late Clinical Stage Products - Universities/Institutes 4.5 Mid Clinical Stage Products

    4.5.1 Comparative Analysis

    4.5.2 Mid Clinical Stage Products - Companies

     Universities/Institutes 4.5.3 Mid Clinical Stage Products -

    4.6 Early Clinical Stage Products

    4.6.1 Comparative Analysis

    4.6.2 Early Clinical Stage Products - Companies 4.6.3 Early Clinical Stage Products - Universities/Institutes 4.7 Pre-clinical and Discovery Stage Products

    4.7.1 Comparative Analysis

    4.7.2 Pre-clinical and Discovery Stage Products - Companies 5 Companies Involved in Hereditary Angieoedema Therapeutics Development

    6 Universities/Institutes Involved in Hereditary Angieoedema Therapeutics Development

    7 Hereditary Angieoedema Therapeutics Assessment 7.1 Assessment by Monotherapy Products

    7.2 Assessment by Combined Therapeutics

    7.3 Assessment by Therapeutic Class

    7.4 Assessment by Route of Administration

    7.5 Assessment by Molecule Type

    7.5.1 Assessment by Biologics/Non-Biologics under Development 8 Late Stage Drug Profiles Company

    8.1 Drug 1 Profile

    8.1.1 Product Description

    8.1.2 Mechanism of Action

    8.1.3 R&D Progress

    9 Late Stage Drug Profiles Universities/Institutes

    9.1 Drug 1 Profile

    9.1.1 Product Description

    9.1.2 Mechanism of Action

    9.1.3 R&D Progress

    10 Hereditary Angieoedema Therapeutics - Discontinued Company Products

    11 Hereditary Angieoedema Therapeutics Featured News

    12 Appendix

    12.1 Research Methodology

12.2 Secondary Research

    12.3 Global Markets Direct Consulting

    12.4 Contact Us

    12.5 Disclaimer

    "

    "1.1 List of Tables

    Table 1: Number of Products under Development, 2010

    Table 2: Hereditary Angieoedema Products under Development

    Comparative Analysis, 2010

    Table 3: Number of Products under Development by Companies, 2010 Table 4: Number of Products under Investigation by

    Universities/Institutes, 2010

    Table 5: Comparative Analysis by Late Clinical Stage Development, 2010

    Table 6: Late Clinical Stage Products Companies, 2010

    Table 7: Late Clinical Stage Products - Universities/Institutes, 2010 Table 8: Comparative Analysis by Mid Clinical Stage Development, 2010 Table 9: Mid Clinical Stage Products - Companies, 2010

     Universities/Institutes, 2010 Table 10: Mid Clinical Stage Products -

    Table 11: Comparative Analysis by Early Clinical Stage Development, 2010

    Table 12: Early Clinical Stage Products - Companies, 2010 Table 13: Early Clinical Stage Products - Universities/Institutes, 2010

    Table 14: Comparative Analysis by Pre-clinical and Discovery Stage Development, 2010

    Table 15: Pre-clinical and Discovery Stage Products - Companies, 2010 Table 16: Companies Involved in Hereditary Angieoedema Therapeutics Development - Company 1

    Table 17: Products under Investigation by Universities/Institutes, 2010

    Table 19: Assessment by Monotherapy Products, 2010

    Table 20: Assessment by Combined Therapeutics, 2010

    Table 21: Assessment by Therapeutic Class, 2010

    Table 22: Assessment by Route of Administration, 2010 Table 23: Assessment by Molecule Type, 2010

    Table 24: Assessment by Biologics/Non-Biologics, 2010 Table 25: Discontinued Company Products

    "

    "1.2 List of Figures

    Figure 1: Number of Products under Development, 2010

    Figure 2: Hereditary Angieoedema Products under Development

    Comparative Analysis, 2010

    Figure 3: Products under Development by Companies, 2010 Figure 4: Products under Investigation by Universities/Institutes, 2010

    Figure 5: Late Clinical Stage Products, 2010

    Figure 6: Mid Clinical Stage Products, 2010

    Figure 7: Early Clinical Stage Products, 2010

    Figure 8: Pre-clinical and Discovery Stage Products, 2010 Figure 9: Assessment by Monotherapy Products, 2010 Figure 10: Assessment by Combined Therapeutics, 2010 Figure 11: Comparative Analysis - Monotherapy and Combined Therapeutics, 2010

    Figure 12: Assessment by Therapeutic Class, 2010 Figure 13: Assessment by Stage and Therapeutic Class, 2010 Figure 14: Assessment by Route of Administration, 2010 Figure 15: Assessment by Stage and Route of Administration, 2010 Figure 16: Assessment by Molecule Type, 2010

    Figure 17: Assessment by Stage and Molecule Type, 2010 Figure 18: Assessment by Biologics/Non-Biologics, 2010"

Report this document

For any questions or suggestions please email
cust-service@docsford.com